A5049231437- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Esophageal and GI Pathology
- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Inflammatory Biomarkers in Disease Prognosis
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Single-cell and spatial transcriptomics
- Diabetes Management and Research
- Immune Response and Inflammation
- Effects of Radiation Exposure
- Metastasis and carcinoma case studies
- Neutropenia and Cancer Infections
- Colorectal Cancer Screening and Detection
- Diabetes Management and Education
- Mobile Health and mHealth Applications
- Medical Imaging Techniques and Applications
- RNA modifications and cancer
- Immune Cell Function and Interaction
- Diagnosis and treatment of tuberculosis
- Epigenetics and DNA Methylation
Fudan University Shanghai Cancer Center
2017-2025
Cloud Computing Center
2025
Shanghai Medical College of Fudan University
2017-2024
Shanghai Clinical Research Center
2023-2024
Shanghai Institute of Hematology
2021-2023
Esophageal squamous cell carcinoma is a major histological type of esophageal cancer, with distinct incidence and survival patterns among races. Although previous studies have characterized somatic mutations in this disease, rigorous comparison between different patient populations has not been conducted. Here we sequence the samples 316 Chinese patients, combine them those from The Cancer Genome Atlas, perform comparative analysis Asian Caucasian patients. We find that mutated CSMD3...
Esophageal cancer is the eighth most common worldwide. The prognosis of esophageal patients dismal, especially those with distant organ metastasis. However, there are few studies describing patterns metastasis in systematically.We gathered data from Surveillance Epidemiology and End Results (SEER) database between 2010 2013. Categorical variables were analyzed by Pearson Chi square test, continuous two-sample t test. Survival estimation comparison among different performed using Kaplan-Meier...
<h3>Importance</h3> Multiple paclitaxel-based regimens are widely used in chemoradiation therapy against esophageal cancer, including combining paclitaxel with fluorouracil, cisplatin, and carboplatin. However, which among these 3 provides the best prognosis minimum adverse events is still unknown. <h3>Objective</h3> To compare efficacy of carboplatin definitive chemoradiotherapy patients squamous cell carcinoma (ESCC). <h3>Design, Setting, Participants</h3> This randomized clinical trial...
Abstract Background Esophageal cancer (EC) is a global health problem. Asia represents huge burden of EC globally, and incidence mortality vary considerably across different Asian regions. Methods Data on incidence, mortality, preference were extracted from GLOBOCAN 2020. Age‐standardized rates calculated overall by sex, age, country, region, continent. The predicted in 2040 was based demographic projections. Results It estimated there 481 552 new cases 434 363 deaths 2020, accounting for...
BackgroundConcurrent chemoradiotherapy is the standard nonoperative treatment for locally advanced esophageal squamous cell carcinoma. However, local recurrence still main failure pattern, accounting more than half of all failures, indicating that sensitivity radiotherapy needs to be improved. This trial aimed at demonstrating whether PD-1 inhibitors followed by could promote tumor vascular normalization, alleviate hypoxia, and thus enhance radiosensitivity improve control.MethodsWe did a...
Background Immunotherapy (Programmed cell death 1 blockade) has entered the ranks of advanced esophageal cancer first-line treatment; however, little is known about efficacy PD-1 inhibitor as neoadjuvant therapy in resectable squamous carcinoma (ESCC). We aim to evaluate activity and safety sintilimab combined with chemotherapy treatment thoracic ESCC. Methods The enrolled patients (clinical stage II IVA) ESCC received injection (200 mg/time, day 1), paclitaxel liposomes (135 mg/m 2 ,...
This study aims to assess the safety and efficacy of stereotactic body radiation therapy (SBRT) for patients with oligometastatic esophageal squamous cell carcinoma (ESCC).From April 2015 December 2018, a prospective, single-arm, phase 2 trial was conducted. The main inclusion criteria were ESCC 3 or fewer metastases controlled primary malignancy after radical treatment, all metastatic lesions amenable SBRT. enrolled assigned SBRT then received chemotherapy at least 4 cycles starting from 0...
ABSTRACT Objective Our study aimed to evaluate the effectiveness of a 3‐months digital therapy (DTx) intervention in real world for management blood glucose 3,902 Chinese patients with type 2 diabetes (T2D) Lingshui, Hainan. Methods Adults T2D who were capable using DTx application (app) enrolled. Fasting (FBG), 2‐h postprandial (2hPBG), and body weight before after collected. Participants recorded at least once weekly, attended education program app during online follow‐up weekly. Results A...
Abstract Purpose: Preclinical model found that elective nodal irradiation (ENI) attenuated the efficacy of radiotherapy and radio-immunotherapy. However, limited clinical studies have explored correlation between radiation dose-volume parameters negative tumor draining lymph nodes (TDLNs) T-cell activation/prognosis for cancer patients treated with definitive radio(chemo)therapy. Experimental Design: Patients locally advanced esophageal undergoing chemoradiotherapy (CRT) were selected from...
Apatinib has potential as an effective and safe second-line or higher treatment for patients with chemotherapy-refractory esophageal squamous cell carcinoma (ESCC). Clinical safety is of concern when administering apatinib to uncontrolled lesions severe invasion trachea, bronchi, major blood vessels. To the best authors' knowledge, this first prospective phase II study investigate ESCC. could provide alternative option ESCC after first-line therapy in carefully selected patients.The aim was...
Limited studies explored the relationship between lymphocyte recovery after definitive concurrent chemoradiotherapy (dCCRT) and prognosis in esophageal squamous cell carcinoma (ESCC).
Liver and lung are the most common metastatic sites for esophageal cancer. Tumor location of cancer has been a prognostic factor tumor, node metastasis (TNM) staging system since 2009. However, relationship between tumor remains unclear.Patients with were derived from surveillance, epidemiology end results (SEER) database 2010 to 2013. Age, sex, histologic type grade included in model propensity score matching patients or without liver metastasis. After matching, probability was analyzed...
This study aimed to explore the relationship between irradiation of lymphocyte-related organs at risk (LOARs) and lymphopenia during definitive concurrent chemoradiotherapy (dCCRT) for esophageal squamous cell carcinoma (ESCC).Cases ESCC patients who received dCCRT from 2 prospective clinical trials were identified. To find its correlation with survival outcomes, grades absolute lymphocyte counts (ALCs) nadir radiotherapy recorded following COX analysis. Associations lymphocytes dosimetric...
Esophageal cancer (EC) is one of the most common cancers worldwide. The prognoses for patients with same stage EC can vary substantially. progress single-cell analysis technology has furthered understanding tumor heterogeneity. This paper aimed to apply explore characteristics environment and provide a basis personalized treatment.The latest gene expression data clinical follow-up information sequencing results samples were downloaded from Cancer Genome Atlas (TCGA) Genomic Data Commons...
Definitive chemoradiotherapy has established the standard non-surgical treatment for locally advanced esophageal cancer. The dose of 50-50.4 Gy been decades ago and confirmed in modern trials. theorical advantage better local control technical advances less toxicity have encouraged clinicians escalation investigation. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) potential to tailor therapy patients not showing response CRT pioneers PET-based...
Abstract Background To compare the efficacy and safety of postoperative extensive target volume irradiation with elevated radiation dose concurrent chemotherapy radiotherapy only for treatment esophageal squamous cell carcinoma. Methods This trial was a single-arm phase II trial. Patients who underwent radical transthoracic resection negative margins within 3 months histologically confirmed carcinoma (pT3-4N0M0 or pTxN + M0, AJCC 7th) were eligible this study. Postoperative performed at...
Concurrent chemoradiation is the standard therapy for patients with local advanced oesophageal carcinoma unsuitable surgery. Paclitaxel an active agent against cancer and it has been proved as a potent radiation sensitiser. There have multiple studies evaluating paclitaxel-based in cancer, of which results are inspiring. However, regimen, among cisplatin (TP), carboplatin (TC) or fluorouracil (TF) combination paclitaxel concurrent radiotherapy, provides best prognosis minimum adverse events...
This trial aims to explore the feasibility and safety of postoperative radiotherapy covering all regional lymph node areas for locally advanced thoracic esophageal squamous cell carcinoma patients treated with intensity-modulated radiation therapy (IMRT).This was a single-center single-arm, phase II clinical initiated in 2014. Patients who were radical transthoracic resection had negative margins within 3 months histologically confirmed (pT3-4 or N+, M0 determined by 7th edition AJCC...
Radiotherapy is a main treatment for esophageal squamous cell carcinoma (ESCC), but radioresistance leads to failure ultimately. The combination of radiotherapy and PD-1 inhibitors showed significant antitumor effects. Our study that high-immune score, IFNG CD8A level were associated with low-radiosensitivity index (RSI) in the TCGA-ESCC cohort. And blocking promoted exhausted T cells proliferation IFN-γ expression. inhibitor-reactivated G2/M-phase arrest, apoptosis impaired DNA damage...
Since 2011, through the Community-Based Colorectal Cancer Screening Program in Shanghai, China (SHcsp), residents aged >50 years were offered initial colorectal cancer screening using fecal immunochemical test (FIT) and risk assessment questionnaire (RAQ) for free. Colonoscopy was then recommended positive results.To evaluate cost-effectiveness of from payer perspective.This analysis estimated long-term cost effectiveness 2014-2016 SHcsp based on real-world follow-up data database, Shanghai...
<title>Abstract</title> Background Anti-PD-1 therapy combined with or without chemotherapy is the standard regimen for metastatic esophageal cancer. Oligometastatic carcinoma an intermediate state of tumor development between locally advanced and widespread metastasis, potential long-term survival. The value addition local intervention to systemic still controversial patients oligometastasis. ESO-Shanghai 13 trial demonstrated that improved progression-free survival overall in...
The optimal evidence-based management for the subsets of locally advanced esophageal squamous cell carcinoma (ESCC) patients who rejected or were intolerant to intravenous chemotherapy due old age serious comorbidities is currently lacking. This study aimed assess safety and local control rate (LCR) S-1 (tegafur-gimeracil-oteracil potassium) combined with radiotherapy in these ESCC patients.Locally >75 years enrolled a prospective, single-arm, phase 2 trial. treated definitive concurrent...